FDA Clearance Tracker · P220014
CraniSeal Dural Sealant
Last checked: Nov 20, 2026Latest source record: Jul 6, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jul 6, 2023
Approved
Time to decision
307 days
Received Sep 2, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P220014
- Device name
- CraniSeal Dural Sealant
- Applicant
- Pramand, LLC
- Applicant location
- Bedford, MA
- Received
- Sep 2, 2022
- Decided
- Jul 6, 2023
- Decision
- Approved
- Supplements
- 13 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Sealant, dural (NQR)
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
Approval for the CraniSeal Dural Sealant. The device is indicated for use in patients >= 18 years of age as an adjunct to sutured dural repair during cranial surgery to provide watertight closure.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NQR. The earliest in FDA's data is P040034, decided Apr 7, 2005.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Pramand, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240027 · Decided Feb 14, 2025 · 179 days after receipt
Device type: Sealant, dural (NQR) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.